TrialPaediatric drugs2025

Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.

Kulli Kingo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.